JP2021516231A5 - - Google Patents
Info
- Publication number
- JP2021516231A5 JP2021516231A5 JP2020545351A JP2020545351A JP2021516231A5 JP 2021516231 A5 JP2021516231 A5 JP 2021516231A5 JP 2020545351 A JP2020545351 A JP 2020545351A JP 2020545351 A JP2020545351 A JP 2020545351A JP 2021516231 A5 JP2021516231 A5 JP 2021516231A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- compound according
- alkyl
- substituted
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862636831P | 2018-02-28 | 2018-02-28 | |
| US62/636,831 | 2018-02-28 | ||
| PCT/US2019/019936 WO2019169065A2 (en) | 2018-02-28 | 2019-02-28 | Wee1 kinase inhibitors and methods of treating cancer using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021516231A JP2021516231A (ja) | 2021-07-01 |
| JP2021516231A5 true JP2021516231A5 (enExample) | 2022-03-09 |
| JP7483620B2 JP7483620B2 (ja) | 2024-05-15 |
Family
ID=67805580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545351A Active JP7483620B2 (ja) | 2018-02-28 | 2019-02-28 | Ｗｅｅ１キナーゼ阻害物質およびそれを使用してがんを処置する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12220415B2 (enExample) |
| EP (1) | EP3758706A4 (enExample) |
| JP (1) | JP7483620B2 (enExample) |
| AU (1) | AU2019227823B2 (enExample) |
| CA (1) | CA3088997A1 (enExample) |
| WO (1) | WO2019169065A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6692423B2 (ja) | 2015-11-01 | 2020-05-13 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト | Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法 |
| CA3070073A1 (en) | 2017-07-18 | 2019-01-24 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| CN111163780A (zh) | 2017-07-18 | 2020-05-15 | 诺维逊生物股份有限公司 | 作为腺苷拮抗剂的杂环化合物 |
| AU2018347307A1 (en) | 2017-10-09 | 2020-04-23 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| EP3694861A4 (en) | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| US12220415B2 (en) | 2018-02-28 | 2025-02-11 | The Regents Of The University Of Colorado, A Body Corporate | WEE1 kinase inhibitors and methods of treating cancer using the same |
| EP4566612A3 (en) | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| AU2020208644A1 (en) | 2019-01-18 | 2021-08-26 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| WO2020150676A1 (en) | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| JP2022526831A (ja) | 2019-04-09 | 2022-05-26 | ニューベイション・バイオ・インコーポレイテッド | ヘテロ環式化合物およびその使用 |
| US20230065577A1 (en) * | 2019-12-20 | 2023-03-02 | Recurium Ip Holdings, Llc | Combinations |
| AU2020404996A1 (en) * | 2019-12-20 | 2022-07-14 | Recurium Ip Holdings, Llc | Combinations |
| CN113402520A (zh) * | 2020-03-16 | 2021-09-17 | 中国科学院上海药物研究所 | Wee1蛋白降解剂 |
| CA3180664A1 (en) * | 2020-06-17 | 2021-12-23 | Yuli Xie | Pyrazolo[3,4-d]pyrimidine-3-one derivative as wee-1 inhibitor |
| EP4349838A4 (en) * | 2021-05-28 | 2025-08-13 | Jiangsu Tasly Diyi Pharmaceutical Co Ltd | WEE1 INHIBITOR AND ITS USE |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB884151A (en) * | 1957-12-06 | 1961-12-06 | Ciba Ltd | New pyrazolo-pyrimidines substituted in the pyrazole nucleus, and process for their manufacture |
| WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
| PE20080695A1 (es) * | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| WO2010104406A1 (en) * | 2009-03-11 | 2010-09-16 | Auckland Uniservices Limited | Prodrug forms of kinase inhibitors and their use in therapy |
| CN102574846B (zh) * | 2009-09-02 | 2014-12-03 | 奥克兰联合服务有限公司 | 激酶抑制剂、其前药形式及它们在治疗中的用途 |
| GB201322602D0 (en) * | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| JP6692423B2 (ja) * | 2015-11-01 | 2020-05-13 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト | Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法 |
| EP3571205B1 (en) | 2017-01-22 | 2023-08-30 | Sunshine Lake Pharma Co., Ltd. | Thienopyrimidine derivative and use thereof in medicine |
| JP6717457B2 (ja) | 2017-01-23 | 2020-07-01 | シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド | Ｗｅｅ１阻害剤としての１，２−ジヒドロ−３Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−３−オン誘導体 |
| MX2020001235A (es) | 2017-08-01 | 2020-07-20 | Recurium Ip Holdings Llc | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. |
| US12220415B2 (en) | 2018-02-28 | 2025-02-11 | The Regents Of The University Of Colorado, A Body Corporate | WEE1 kinase inhibitors and methods of treating cancer using the same |
-
2019
- 2019-02-28 US US16/975,818 patent/US12220415B2/en active Active
- 2019-02-28 WO PCT/US2019/019936 patent/WO2019169065A2/en not_active Ceased
- 2019-02-28 AU AU2019227823A patent/AU2019227823B2/en active Active
- 2019-02-28 CA CA3088997A patent/CA3088997A1/en active Pending
- 2019-02-28 JP JP2020545351A patent/JP7483620B2/ja active Active
- 2019-02-28 EP EP19760397.0A patent/EP3758706A4/en not_active Withdrawn
-
2024
- 2024-12-20 US US18/991,248 patent/US20250186447A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021516231A5 (enExample) | ||
| EP2101759B1 (en) | Methods of using mek inhibitors | |
| ES2660263T5 (en) | Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments | |
| US11001564B2 (en) | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | |
| RU2021103727A (ru) | Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией | |
| CN107406417A (zh) | 4H‑吡咯并[3,2‑c]吡啶‑4‑酮衍生物 | |
| US20190142812A1 (en) | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | |
| JP2012501312A5 (enExample) | ||
| JP2015530975A5 (enExample) | ||
| WO2018122168A1 (en) | Combinations of bub1 kinase and parp inhibitors | |
| JP2013501790A5 (enExample) | ||
| JP2020507606A5 (enExample) | ||
| RU2012147511A (ru) | Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза | |
| JP2021524844A5 (enExample) | ||
| CA2526989A1 (en) | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | |
| WO2018153971A1 (en) | Combination of atr kinase inhibitors | |
| KR20080004495A (ko) | 암을 치료하기 위한 조합물, 방법 및 조성물 | |
| WO2016205460A4 (en) | Polycyclic derivatives targeting ral gtpases and their therapeutical applications | |
| JP2018519332A5 (enExample) | ||
| WO2016087490A1 (en) | Combination of pi3k-inhibitors | |
| CA2553704A1 (en) | Substituted benzimidazoles and their use for inducing apoptosis | |
| RU2382784C2 (ru) | Новые пиперидинзамещенные диаминотиазолы | |
| RU2008127264A (ru) | Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза | |
| US20210369724A1 (en) | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds | |
| JP2025517442A5 (enExample) |